Citius Pharmaceuticals, Inc. Email Format

Pharmaceutical ManufacturingNew Jersey, United States11-50 Employees

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing first-in-class critical care products. Its pipeline includes anti-infectives used in adjunct cancer care, stem cell therapies, and other distinctive prescription medicines. The company is based in Cranford, New Jersey, and operates within the pharmaceutical manufacturing industry. 

In 2024, Citius Pharmaceuticals completed a merger with TenX Keane Acquisition to form the publicly listed Citius Oncology, Inc. In July 2025, the company launched LYMPHIR, an FDA-approved cancer drug, as part of its commercial operations. This development aligns with its ongoing emphasis on delivering innovative therapies for critical care and cancer-associated indications.

Sign up for free to view info

Company overview Employee directory